Seeking Alpha EN

Relmada wins bullish view at Piper Sandler on cancer therapy

Mar 24, 2026 &03312424202631; 18:31 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↗

Positive for markets

Sentiment score: +65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Piper Sandler initiates bullish coverage on Relmada's cancer therapy, a fresh positive catalyst for the biotech stock. However, VIX is elevated (+2.72%) and S&P 500 shows minimal movement, suggesting limited market enthusiasm for risk assets.

AI CONFIDENCE

62% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

RLMD

RLMDStock

Expected to rise

Fresh bullish analyst initiation from Piper Sandler on cancer therapy; positive catalyst for small-cap biotech with limited immediate market reaction

⇅

S&P 500

^GSPCIndex

High volatility expected

Elevated VIX (+2.72%) and flat S&P performance suggest risk-off sentiment; biotech upside may be offset by broader market caution

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

RLMD may see 2-3% upside on analyst initiation, but elevated VIX and flat broad market suggest limited follow-through. Wait for volume confirmation before entering; risk/reward is moderate given macro headwinds. [MOVE:2.5%]

KEY SIGNALS

Fresh analyst bullish initiation (9 min old)Elevated VIX suggests risk-off environmentS&P 500 flat despite positive newsSmall-cap biotech typically volatile on analyst calls

SECTORS INVOLVED

HealthcareBiotechnology

Analysis generated on Mar 24, 2026 at 18:40 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Relmada wins bullish view at Piper Sandler on cancer therapy

RELATED INTELLIGENCE